Member Info for violindog

Scinv, perhaps us long term holders are more relaxed , Scancell don't have a good record keeping to timescales...... but they have always delivered 100% when results arrive 😁

Yes, 25 does = 3rd scan , but if you have shown a meaningful response at the 1st and 2nd ...then the 3rd can be predicted??

So after the last pt recruited a CT @ 12 weeks. By now Scancell must have enough info to statistically forsee the potential results at 3/4.5 and six months.

You have a CT scan at:

the start of the trial

3 months

4½ months

6 months and then

every 3 months after that

There are only 7 useful working weeks left of 2024. I personally don't think it will cause too much concern if results slip into January 25. Waited decades for this result 🤣. I hope Scancell also "push" the positive data from the very original scib trial...prolonged survival etc etc

EE, my wallet says sell and cut your loss before it goes lower, but my heart, after all these years of holding through thick and thin... says hold . Yes..irrational 😕

EE,

"Would you call yourself a depressive? "

When it comes to the SP of Scancell.....certainly ... very depressed indeed . Nov/ Dec/ Jan , only 12 weeks to go ..boom or bust !

.... and the slow grind down continues despite good RNSs and potential. If we don't get results soon we will be sub 10p and it's going to take a momentous shift to get us back to over 20p . Even a 100% gain on today's price is still derisory and doesn't even take us to Trinity value.

Fed up and lowering my exit to 30p if it ever gets there !

Well, certainly no stampeed for Scancells shares post AGM . Everyone waiting on the sidelines until results I guess .

It would be great if the UK had some legislation similar to the USA introduced under President Trump...the ability to have trial drugs without prejudice to the company. I can't remember exactly how the legislation was worded but it certainly gave early access to promising trial drugs .

Ipad, I agree with you. I think it was Berm ( apologies if not ) who stated the upfront payment was low because it was a novel product , but it broke the ice for potential further deals.

Did Goodfellow get Scancell a good deal ? Well compared to the deals Marcus keeps posting on the other BB .... it does seam a very, very low initial payment. If it was the case that it was the ice breaker ....we can only be grateful that we have the next potential deal lined up under the current £1m / $1m ( was it dollars or stirling) exclusivity payment . Either the low upfront set a president for this platform or the new management team post Goodfellow have secured an excellent deal ... the sort Marcus post about.

Anyway... not long now to wait before we find out.

If Scancell get excellent trial results prior to the "decision " we may not appear to be so vulnerable and hence we could negotiate harder... but I think LD said the deal was already done and it was simply a case of ...yes ..or ..no ?

Https://www.fiercebiotech.com/biotech/arcus-new-hif-2a-data-kidney-cancer-hint-potential-edge-over-mercks-welireg-analysts-say

Hi Guys, firstly thanks for the AGM feedback.

The link above gives some insight to the competition Modi has in relation to renal cancer .

Berm, but yes, other than this snippet... not much info regarding other cohorts etc

Berm, the presentation does state 6 renal cell carcinoma pts have so far been treated with Modi

Another purchase ....

Modifi...is so similar to Modi... perhaps they bought the wrong company 🤣🤣

New Haven, Connecticut-based Modifi is a pre-clinical stage company, which develops cancer therapies that aim to selectively kill cancer cells by modifying cancer DNA.

Modifi has raised $10.7 million to date in seed funding and is backed by investors including American Cancer Society's investment arm, BrightEdge.

Merck has been in pursuit of eligible candidates that could potentially make up for a loss of revenue from its aging blockbuster cancer immunotherapy, Keytruda, which is set to lose its patent protection by the end of the decade.

https://www.reuters.com/business/healthcare-pharmaceuticals/merck-buys-cancer-therapy-developer-modifi-biosciences-up-13-bln-2024-10-23/

Crusty, DeAar, I expect that you are both correct and hopefully good SCOPE data will result in a sustained SP rise , giving Scancell a strong negotiating position.

Johny...yes , last year SCOPE update on the 28th, AGM 29th .....and then Fundraising RNS on the 30th ! I hope history doesn't repeat itself.

Someone offloading driving the SP down and increasing the spread . Its a shame.... I had hoped for some momentum after yesterday's RNS and the impending AGM.

Hi Roses, a worked buy or sell ?

Great news today... another big step forward to my 50p 😀

There's still an opportunity 🙏

"Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for $600 million, it said ahead of its Capital Markets day on Thursday.

"Our guiding principle is and always has been, the right target, at the right time, for the right price," CEO Belen Garijo said in a statement.

"For larger future transactions, Merck is focusing on the Life Science business sector," the firm added."

https://www.reuters.com/business/healthcare-pharmaceuticals/merck-lowers-mid-term-healthcare-outlook-after-recent-drug-failures-2024-10-17/